Last updated: 2026-10-13 12:29:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Vogenx Inc. (VOGX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $16,80, with a market capitalisation of $260,86M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $12,95 to $38,41. This page covers its latest market performance, valuation, price trends and company information.
$260,86M | |
$17,19 | |
$38,41 | |
$12,95 | |
$17,14 | |
-- | |
182,82K | |
-- | |
$38,41 | |
$12,95 | |
-- | |
-- |
Vogenx Inc. (VOGX) is trading at $16,80 in pre-market trading as of 2026-10-13 08:12:00, down 1,98% ($0,34) from the previous close of $17,14
Pre-market trading shows how investors are pricing VOGX before the regular session opens. The current pre-market price is below the previous close, indicating cautious early trading sentiment.
Over the past seven days, Vogenx Inc. (VOGX) moved from $18,23 to $16,80, representing a decline of 7,84% ($1,43).
The stock traded between $14,56 and $21,00 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 98,41 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 15,1%
VOGX is currently trading at $16,80, placing it 15,1% of the way from its 52-week low of $12,95 to its 52-week high of $38,41. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 5 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Vogenx Inc. (VOGX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.